RDY

Dr. Reddy's Laboratories Limited

$14.86

-1.26%

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements.

Source: Yahoo Finance
AI summary

Price & performance

1M+17.9%
3M+19.7%
YTD+5.6%
1Y+9.2%
52-week range—
Beta0.39
Full chart and returns against a benchmark

Q-Score

70/ 100

Quality against peers; 50 is the peer median.

Growth55
Risk86
Performance46
Valuation60
Profitability76
Leverage72
Sentiment32
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$3.8B+13.8%
Net income$671M+0.4%
Net margin17.6%-2.3 pts
Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

RDYIndustryP/E18.4635.25P/S3.252.74EV/EBITDA12.7716.35P/B3.172.46PEG41.110.87
Dividend yield0.63%
Every valuation metric

Earnings

Jan 21next report, before the open
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate